{
    "id": 3162,
    "name": "malignant spindle cell melanoma",
    "source": "DOID",
    "definition": "A melanoma that is composed of spindled neoplastic cells arranged in sheets and fascicles. [url:https\\://www.ncbi.nlm.nih.gov/pmc/articles/PMC6144801/]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:3162",
    "evidence": [
        {
            "id": 6294,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RG7386 treatment of malignant spindle cell melanoma cell line xenograft models positive for Fap resulted in tumor growth inhibition (PMID: 27037412).",
            "molecularProfile": {
                "id": 23089,
                "profileName": "FAP positive"
            },
            "therapy": {
                "id": 4110,
                "therapyName": "RG7386",
                "synonyms": null
            },
            "indication": {
                "id": 3162,
                "name": "malignant spindle cell melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5521,
                    "pubMedId": 27037412,
                    "title": "RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27037412"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12788,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, PD-1 blockade therapies including Keytruda (pembrolizumab), Opdivo (nivolumab), and BMS-936559 (alone or in combination) resulted in complete response in 32% (19/60), and partial response in 38% (23/60) of malignant spindle cell melanoma patients, whose tumors contained a high percentage of CD274-positive cells (PMID: 29320474).",
            "molecularProfile": {
                "id": 4746,
                "profileName": "CD274 positive"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 3162,
                "name": "malignant spindle cell melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10715,
                    "pubMedId": 29320474,
                    "title": "High response rate to PD-1 blockade in desmoplastic melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29320474"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12789,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, PD-1 blockade therapies including Keytruda (pembrolizumab), Opdivo (nivolumab), and BMS-936559 (alone or in combination) resulted in complete response in 32% (19/60), and partial response in 38% (23/60) of malignant spindle cell melanoma patients, whose tumors contained a high percentage of CD274-positive cells (PMID: 29320474).",
            "molecularProfile": {
                "id": 4746,
                "profileName": "CD274 positive"
            },
            "therapy": {
                "id": 1312,
                "therapyName": "Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 3162,
                "name": "malignant spindle cell melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10715,
                    "pubMedId": 29320474,
                    "title": "High response rate to PD-1 blockade in desmoplastic melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29320474"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12790,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, PD-1 blockade therapies including Keytruda (pembrolizumab), Opdivo (nivolumab), and BMS-936559 (alone or in combination) resulted in complete response in 32% (19/60), and partial response in 38% (23/60) of malignant spindle cell melanoma patients, whose tumors contained a high percentage of CD274-positive cells (PMID: 29320474).",
            "molecularProfile": {
                "id": 4746,
                "profileName": "CD274 positive"
            },
            "therapy": {
                "id": 3339,
                "therapyName": "BMS-936559",
                "synonyms": null
            },
            "indication": {
                "id": 3162,
                "name": "malignant spindle cell melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10715,
                    "pubMedId": 29320474,
                    "title": "High response rate to PD-1 blockade in desmoplastic melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29320474"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16376,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, treatment with Mekinist (trametinib) resulted in some decrease in lesion size and number in a patient with spitzoid melanoma harboring MAP3K8-GNG2, however, the patient experienced cardiotoxicity and efficacy did not continue, and Mekinist (trametinib) therapy was discontinued (PMID: 30833747).",
            "molecularProfile": {
                "id": 31617,
                "profileName": "MAP3K8 - GNG2"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3162,
                "name": "malignant spindle cell melanoma",
                "source": "DOID"
            },
            "responseType": "unknown",
            "references": [
                {
                    "id": 14474,
                    "pubMedId": 30833747,
                    "title": "Clinical genome sequencing uncovers potentially targetable truncations and fusions of MAP3K8 in spitzoid and other melanomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30833747"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT02775851",
            "title": "Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        }
    ]
}